On October 14, 2020 Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, reported a late-breaking presentation at the 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Virtual Symposium being held October 24-25, 2020 (Press release, Rain Therapeutics, OCT 14, 2020, View Source [SID1234568516]). The oral presentation will provide an update on data from the Phase 1 clinical trial of RAIN-32 (Milademetan), an oral MDM2 inhibitor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additional presentation details can be found below:
Oral Presentation
Title: Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
Session Title: New Drugs on the Horizon
Presenter: Mrinal M. Gounder, M.D., Memorial Sloan Kettering Cancer Center
Session Date: Sunday, October 25
Session Time: 9:00 p.m. – 10:45 p.m. CET/4:00 p.m.-5:45 p.m. EDT
Presentation Time: 10:00 p.m. CET/5:00 p.m. EDT
The session will be followed by a Q&A from 10:10 p.m.to 10:30 p.m. CET/5:10 p.m. to 5:30 p.m. EDT. Additional details can be found on the conference website.
About RAIN-32
RAIN-32 has been evaluated in patients with various solid tumors, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and has received Orphan Drug Designation for the treatment of liposarcoma. RAIN-32 also has been evaluated in continuous and intermittent dose schedules that may offer a differentiated tolerability profile as compared to other MDM2 programs.
A separate clinical study for RAIN-32 is ongoing to evaluate safety and efficacy in patients with FLT3-ITD AML in combination with the FLT3 inhibitor, quizartinib. In addition, multiple investigator sponsored studies are being conducted by MD Anderson Cancer Center (MDACC) as well as National Cancer Center Hospital (NCCH) in Tokyo, Japan.